Long-term health follow-up for people who received gene therapy vaccines
Follows people who received poxviral vaccines in earlier cancer studies, checking health yearly.
Key facts
- Who runs it
- National Cancer Institute (NCI)
- Where
- Bethesda, United StatesSee the site
- Trial code
- Registry title
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
- Status
- Recruiting
- People taking part
- 750 people, planned
- Started
- 13 Sept 2004
- Type of study
- Observational
- Record updated
- 9 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who earlier received poxviral vector vaccines or other gene transfer or immunotherapy agents in National Cancer Institute trials. It only follows their health over many years.
- Age
- 18 years or older
- Sex
- All sexes can join
- Earlier treatment
- Must have received poxviral vectors (vaccinia and/or fowlpox) or other gene transfer or immunotherapy vaccines in an NCI-affiliated trial, or at an outside site in a multi-site trial.
Main reasons for not taking part
- People who are unwilling to take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who cannot take part
- Participants unwilling to participate
- (Please note, participants may participate in this protocol and, at the same time, participate in an active treatment or continuing care study.)
Other criteria
- INCLUSION CRITERIA:
- Subjects who received poxviral vectors (vaccinia and/or fowlpox) or other vaccines utilizing gene transfer or any other immunotherapeutic agent through GMB, UOB and LTIB affiliated trials at the National Cancer Institute, as well as subjects at extramural sites receiving these agents as part of a multi-site trial. Available stored specimens obtained from NCI participants in GMB, UOB, and LTIB affiliated protocols may be transferred to this protocol for storage and eventual future research use
- Subjects must be >= 18 years of age
Where in United States
- National Institutes of Health Clinical CenterBethesda, United StatesContact: Sheri A McMahon, R.N.Taking people
About the trial
What the trial wants to find out
This study aims to provide long-term follow-up care of patients previously enrolled in a vaccine study that involved poxviral vectors. Vectors are sequences of genetic material that can be used to introduce specific genes into genetic makeup. The study does not involve the use of any drug or biologic agent. Participants will undergo an annual health history. Because certain viruses enter into cells and create proteins from the viral genes, the type of vaccine treatment used is referred to gene therapy. The genes expressed by poxviral vectors do not become part of the genetic material left behind. Because gene therapy is a somewhat new technology, a prolonged monitoring of patients' health status is necessary, according to new specific reporting requirements for harmful events in patients who undergo such gene therapy studies. The risk of any long-term negative effects from the gene therapy that patients had received is quite small. Still, it is important that there be updates at least annually. This annual monitoring of health status will extend for 15 years, according to guidelines from the Food and Drug Administration, or for as long as patients are willing to participate.
Read full original descriptionShow less
Patients who received poxviral vectors (vaccinia or fowlpox, or both) at the National Cancer Institute, through a trial affiliated with the Laboratory of Tumor Immunology and Biology, may be eligible for this study.
Participants will be involved in the following forms of data collection:
* Annual medical history and physical examinations for the first 5 years following the last vaccine. * Annual telephone contact during the last 10 years. * Health status check, including primary cancer status, secondary malignancies, neurologic disorders, autoimmune disorders, and hematologic disorders. * Blood tests for the presence of HIV antibodies. * Reporting of medical problems, including information on unexpected hospitalizations and medications.
If a participant has died, the study will document the cause of death and autopsy information if available.
The group in the trial
- Cohort 1
Subjects previously participating in gene transfer or other immunotherapy studies at the NCI or extramural sites receiving therapeutic agents as part of a multi-site trial.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Follow-Up Study of Subjects Previously Enrolled in Immunotherapy Studies Utilizing Gene Transfer or Other Immunotherapeutic Agents
- Plain-language title
- Long-term health follow-up for people who received gene therapy vaccinesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 9 November 2026